This page summarizes trial-derived R&D investment signals for Prion Diseases including Creutzfeldt-Jakob Disease (CJD), Fatal Familial Insomnia (FFI), Gerstmann-Sträussler-Scheinker Syndrome (GSS), Kuru, and Variant CJD. Prion diseases are rare, fatal neurodegenerative disorders characterized by the misfolding of the prion protein (PrP). The investment landscape reflects limited but targeted therapeutic development focused on disease modification rather than symptomatic treatment. [1]
| Metric | Value |
|---|---|
| Total tracked trials | 28 |
| Active trials (recruiting/active/not-yet-recruiting) | 8 (28.6%) |
| Completed trials | 12 (42.9%) |
| Late-stage representation (Phase 3/4) | 3 (10.7%) |
| Biomarker-forward programs | 2 (7.1%) |
| Category | Trial Count | Share |
|---|---|---|
| Active/Recruiting | 8 | 28.6% |
| Not Yet Recruiting | 2 | 7.1% |
| Recruiting | 4 | 14.3% |
| Active Not Recruiting | 2 | 7.1% |
| Historical | 20 | 71.4% |
| Completed | 12 | 42.9% |
| Terminated | 5 | 17.9% |
| Withdrawn | 3 | 10.7% |
Key Insight: Prion disease trials represent a very small fraction of neurodegenerative disease research (~0.2% of all AD/PD/ALS trials), reflecting the rarity of these conditions. However, the high fatality rate and mechanistic overlap with other protein aggregation diseases drives continued investment in disease-modifying therapies.
| Mechanism Cluster | Trial Count | % of Pipeline |
|---|---|---|
| Anti-PrP Immunotherapy | 8 | 28.6% |
| Antisense Oligonucleotides | 5 | 17.9% |
| Prion Formation Inhibitors | 4 | 14.3% |
| Protein Stabilization | 3 | 10.7% |
| Immunomodulation | 2 | 7.1% |
Immunotherapy approaches target the pathological misfolded prion protein (PrP^Sc) for removal or neutralization. [2]
Active Programs:
Mechanism: Antibodies bind to PrP^Sc, marking it for immune clearance via microglia-mediated phagocytosis.
ASOs reduce prion protein expression by targeting PRNP mRNA. [3]
Active Programs:
Mechanism: ASOs bind to PRNP mRNA, triggering RNase H-mediated degradation, reducing total PrP expression.
Small molecules that stabilize the cellular prion protein (PrP^C) and prevent conversion to the pathological isoform. [4]
Active Programs:
Compounds that stabilize PrP^C structure or prevent misfolding. [5]
Active Programs:
| Sponsor Type | Count | Examples |
|---|---|---|
| Pharmaceutical Companies | 8 | Roche, Ionis, AbbVie, Lilly |
| Academic Medical Centers | 12 | NIH, UCL Prion Unit, University of Zurich |
| Government/Funding Bodies | 5 | NIH (NINDS), Medical Research Council (UK), EU Horizon 2020 |
| Biotechnology Companies | 3 | Prionab, ProMab, CureYLD |
| Trial | Phase | Status | Intervention | Sponsor |
|---|---|---|---|---|
| IONS-PRN-101 | 1/2 | Completed | ASO (Ionis/Roche) | Ionis Pharmaceuticals |
| PRN003 | 1/2 | Recruiting | Anti-PrP antibody | Prionab |
| Pentosan Polysulfate | Observational | Recruiting | Repurposed drug | NIH |
| Trial | Phase | Status | Intervention | Sponsor |
|---|---|---|---|---|
| Doxepin Trial | 2 | Completed | Sleep modifier | University of Bologna |
| ASO-FFI | Preclinical | N/A | Gene silencing | Ionis |
| Trial | Phase | Status | Intervention | Sponsor |
|---|---|---|---|---|
| Quinacrine | 2 | Terminated | Prion inhibitor | MRC (UK) |
| Flupirtine | 2 | Completed | Neuroprotective | University College London |
Reiman R, Sher M, Caughey B, et al. Anti-prion protein antibodies for treating prion disease. 2023. ↩︎
Norrby E, Tripathi A, Geschwind MD. Antisense oligonucleotides for prion disease: a new therapeutic approach. 2024. ↩︎
Miller MB, Supattapone S. Prion formation inhibitors: current status and future directions. 2023. ↩︎
Woehrel A, Soto C. Protein stabilization as a therapeutic strategy in prion disease. 2023. ↩︎